<DOC>
	<DOCNO>NCT02752646</DOCNO>
	<brief_summary>This study examine tolerability toxicity topically apply Nepafenac 0.3 % v ketorolac 0.5 % among patient undergo cataract surgery .</brief_summary>
	<brief_title>Tolerability Toxicity Topically Applied Nepafenac 0.3 % v Ketorolac 0.5 %</brief_title>
	<detailed_description>This randomize , prospective , control , open-label study , compare tolerability toxicity two commercially available non-steroidal anti-inflammatory eye drop , nepafenac 0.3 % ketorolac 0.5 % ( generic formulation ) . The study involve one eye subject . The study follow good clinical practice ( GCP ) . The primary outcome measure tolerability study medication measure eye drop comfort survey instrument .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Patients 18 year older currently undergo femtosecond manual cataract surgery without astigmatic keratotomy . 2 . Patients willing take electronic survey tolerability either study medication . Exclusion Criteria 1 . Active , systemic local disease condition cause clinically significant ocular surface irritation could interfere question survey examination finding . 2 . Any following ocular ( eye eyelid ) condition either eye within 1 Months prior enrollment visit : 1 . Ocular surgery ( e.g. , intraocular , oculoplastic , corneal refractive surgery procedure . 2 . Clinically significant ocular trauma . 3 . Active ocular Herpes simplex Herpes zoster ( eye eyelid ) infection . 4 . Ocular inflammation ( uveitis , iritis , scleritis , episcleritis , keratitis , conjunctivitis ) 5 . Ocular infection ( e.g. , viral , bacterial , mycobacterial , protozoan fungal infection cornea , conjunctiva , lacrimal gland , lacrimal sac eyelid include hordeolum/stye ) 3 . Moderate severe ( Grade 24 ) allergic , vernal giant papillary conjunctivitis 4 . Severe ( Grade 3 4 ) inflammation eyelid ( e.g. , blepharochalasis , staphylococcal blepharitis seborrheic blepharitis ) 5 . Eyelid abnormality significantly affect lid function ( e.g. , entropion , ectropion , tumor , edema , blepharospasm , lagophthalmos , severe trichiasis , severe ptosis ) 6 . Ocular surface abnormality may compromise corneal integrity ( e.g. , prior chemical burn , recurrent corneal erosion , corneal epithelial defect , Grade 3 corneal fluorescein staining , map dot fingerprint dystrophy ) 7 . Participation another ophthalmic clinical trial involve therapeutic drug device within 30 day prior distribution survey 8 . Participation trial patient 's fellow eye . 9 . Patients pregnant breastfeeding may become pregnant participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cataract</keyword>
</DOC>